JIMD Reports (Jul 2024)

Screening and surveillance of hepatocellular carcinoma by serum des‐gamma‐carboxy prothrombin in patients with glycogen storage disease type Ia

  • A. B. Schreuder,
  • R. J. Overduin,
  • N. C. Peltenburg,
  • L. deBoer,
  • F. A. J. A. Bodewes,
  • T. G. J. Derks

DOI
https://doi.org/10.1002/jmd2.12414
Journal volume & issue
Vol. 65, no. 4
pp. 207 – 211

Abstract

Read online

Abstract No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha‐fetoprotein and carcino‐embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des‐gamma‐carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

Keywords